Core Insights - Atea Pharmaceuticals is presenting updates on its clinical programs for hepatitis C and hepatitis E at the 44th Annual JPMorgan Healthcare Conference [1][2]. Group 1: Hepatitis C Program - The company is executing a global Phase III program for the treatment of hepatitis C, with a pivotal year anticipated in 2026 [3]. - Bemnifosbuvir, discovered seven years ago, is nearing the completion of its first trial, C-BEYOND, which has enrolled over 900 patients [3]. - Results from the C-BEYOND trial are expected in mid-2026, specifically in Q3 [3]. Group 2: Hepatitis E Program - Atea Pharmaceuticals is also advancing a new program for the treatment of hepatitis E, although specific details on this program were not elaborated in the provided text [2].